Benefits of Modest Weight Loss on the Management of Type 2 Diabetes Mellitus

Canadian Journal of Diabetes

Volumn 37, Issue 2, 2013, Pages 128-134

  Lau, David C W ^a   Teoh, Hwee ^b  

^a UNIVERSITY OF CALGARY   (Canada)

^b ST MICHAEL'S HOSPITAL   (Canada)

Author keywords

Dietary therapy; Health behaviour modification; Modest weight loss; Obesity; Overweight; Physical activity; Type 2 diabetes mellitus

Indexed keywords

ANTILIPEMIC AGENT; CANAGLIFLOZIN; DAPAGLIFLOZIN; DIPEPTIDYL PEPTIDASE IV INHIBITOR; EXENDIN 4; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; INSULIN; LIRAGLUTIDE; METFORMIN; PLACEBO; SODIUM GLUCOSE COTRANSPORTER 2; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR; TETRAHYDROLIPSTATIN; UNCLASSIFIED DRUG; ANTIDIABETIC AGENT;

ANTIDIABETIC ACTIVITY; BARIATRIC SURGERY; BEHAVIOR CHANGE; BODY FAT; BODY MASS; CALORIC INTAKE; COST BENEFIT ANALYSIS; COST OF ILLNESS; DISEASE ASSOCIATION; DRUG EFFECT; DRUG EFFICACY; GLYCEMIC CONTROL; HEALTH PROMOTION; HUMAN; IMPAIRED GLUCOSE TOLERANCE; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RESISTANCE; LIFESTYLE MODIFICATION; METABOLIC REGULATION; METABOLIC SYNDROME X; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PATHOPHYSIOLOGY; PREVALENCE; REVIEW; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; SIDE EFFECT; THERAPY EFFECT; WEIGHT CHANGE; WEIGHT GAIN; WEIGHT REDUCTION; CANADA; DIABETES MELLITUS, TYPE 2; DIET THERAPY; HEALTH BEHAVIOR; PHYSIOLOGY;

BARIATRIC SURGERY; CANADA; DIABETES MELLITUS, TYPE 2; DIET THERAPY; HEALTH BEHAVIOR; HUMANS; HYPOGLYCEMIC AGENTS; WEIGHT LOSS;

EID: 84876797600     PISSN: 14992671     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jcjd.2013.03.023     Document Type: Review

References (57)

1. Defronzo R.A. Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes 2009, 58:773-795.
2. Sarwar N., Gao P., et al. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet 2010, 375:2215-2222. Emerging Risk Factors.
3. Finucane M.M., Stevens G.A., Cowan M.J., et al. National, regional, and global trends in body-mass index since 1980: systematic analysis of health examination surveys and epidemiological studies with 960 country-years and 9.1 million participants. Lancet 2011, 377:557-567.
4. Whiting D.R., Guariguata L., Weil C., et al. IDF diabetes atlas: global estimates of the prevalence of diabetes for 2011 and 2030. Diabetes Res Clin Pract 2011, 94:311-321.
5. Chan J.M., Rimm E.B., Colditz G.A., et al. Obesity, fat distribution, and weight gain as risk factors for clinical diabetes in men. Diabetes Care 1994, 17:961-969.
6. Colditz G.A., Willett W.C., Rotnitzky A., et al. Weight gain as a risk factor for clinical diabetes mellitus in women. Ann Intern Med 1995, 122:481-486.
7. Narayan K.M., Boyle J.P., Thompson T.J., et al. Effect of BMI on lifetime risk for diabetes in the U.S. Diabetes Care 2007, 30:1562-1566.
8. Public Health Agency of Canada and the Canadian Institute for Health Information Obesity in Canada 2011, Public Health Agency of Canada, Ottawa.
9. Public Health Agency of Canada Diabetes in Canada. Facts and figures from a public health perspective 2011, Public Health Agency of Canada, Ottawa.
10. Lau D.C.W. "Let's take control of diabetes. Now." Why and How?. Can J Diabetes 2010, 34:317-319.
11. Lau D.C.W. Fight diabetes: the Tsunami of noncommunicable diseases. Can J Diabetes 2009, 33:348-349.
12. Buse J.B., Ginsberg H.N., Bakris G.L., et al. Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from the American Heart Association and the American Diabetes Association. Diabetes Care 2007, 30:162-172.
13. Canadian Diabetes Association Clinical Practice Guidelines Expert Committee, Canadian Diabetes Association 2008 clinical practice guidelines for the prevention and management of diabetes in Canada. Can J Diabetes 2008, 32:S1-S201.
14. Lau D.C., Douketis J.D., Morrison K.M., et al. 2006 Canadian clinical practice guidelines on the management and prevention of obesity in adults and children [summary]. CMAJ 2007, 176:S1-S13.
15. Rodbard H.W., Blonde L., Braithwaite S.S., et al. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the management of diabetes mellitus. Endocr Pract 2007, 13(Suppl 1):1-68.
16. American Diabetes Association Executive Summary: standards of medical care in diabetes-2013. Diabetes Care 2013, 36:S4-S10.
17. Wing R.R., Koeske R., Epstein L.H., et al. Long-term effects of modest weight loss in type II diabetic patients. Arch Intern Med 1987, 147:1749-1753.
18. Leibel R.L., Rosenbaum M., Hirsch J. Changes in energy expenditure resulting from altered body weight. N Engl J Med 1995, 332:621-628.
19. Hall K.D. Body fat and fat-free mass inter-relationships: Forbes' theory revisited. Br J Nutr 2007, 97:1059-1063.
20. Hall K.D., Sacks G., Chandramohan D., et al. Quantification of the effect of energy imbalance on body weight. Lancet 2011, 378:826-837.
21. Ross R., Dagnone D., Jones P.J., et al. Reduction in obesity and related comorbid conditions after diet-induced weight loss or exercise-induced weight loss in men. A randomized, controlled trial. Ann Intern Med 2000, 133:92-103.
22. Anderson J.W., Kendall C.W., Jenkins D.J. Importance of weight management in type 2 diabetes: review with meta-analysis of clinical studies. J Am Coll Nutr 2003, 22:331-339.
23. Lindstrom J., Ilanne-Parikka P., Peltonen M., et al. Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention: follow-up of the Finnish Diabetes Prevention Study. Lancet 2006, 368:1673-1679.
24. Wadden T.A., Butryn M.L., Wilson C. Lifestyle modification for the management of obesity. Gastroenterology 2007, 132:2226-2238.
25. Sumithran P., Prendergast L.A., Delbridge E., et al. Long-term persistence of hormonal adaptations to weight loss. N Engl J Med 2011, 365:1597-1604.
26. Knowler W.C., Fowler S.E., Hamman R.F., et al. 10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet 2009, 374:1677-1686.
27. Unick J.L., Beavers D., Jakicic J.M., et al. Effectiveness of lifestyle interventions for individuals with severe obesity and type 2 diabetes: results from the Look AHEAD trial. Diabetes Care 2011, 34:2152-2157.
28. Stern J.S., Hirsch J., Blair S.N., et al. Weighing the options: criteria for evaluating weight-management programs. The Committee to Develop Criteria for Evaluating the Outcomes of Approaches to Prevent and Treat Obesity. Obes Res 1995, 3:591-604.
29. Wing R.R., Lang W., Wadden T.A., et al. Benefits of modest weight loss in improving cardiovascular risk factors in overweight and obese individuals with type 2 diabetes. Diabetes Care 2011, 34:1481-1486.
30. Knowler W.C., Barrett-Connor E., Fowler S.E., et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002, 346:393-403.
31. Tuomilehto J., Lindstrom J., Eriksson J.G., et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001, 344:1343-1350.
32. Lindstrom J., Louheranta A., Mannelin M., et al. The Finnish Diabetes Prevention Study (DPS): lifestyle intervention and 3-year results on diet and physical activity. Diabetes Care 2003, 26:3230-3236.
33. Gillies C.L., Abrams K.R., Lambert P.C., et al. Pharmacological and lifestyle interventions to prevent or delay type 2 diabetes in people with impaired glucose tolerance: systematic review and meta-analysis. BMJ 2007, 334:299-301.
34. Norris S.L., Zhang X., Avenell A., et al. Long-term non-pharmacological weight loss interventions for adults with type 2 diabetes mellitus. Cochrane Database Syst Rev 2005, 2:CD004095.
35. Pi-Sunyer X., Blackburn G., Brancati F.L., et al. Reduction in weight and cardiovascular disease risk factors in individuals with type 2 diabetes: one-year results of the look AHEAD trial. Diabetes Care 2007, 30:1374-1383.
36. Wing R.R. Long-term effects of a lifestyle intervention on weight and cardiovascular risk factors in individuals with type 2 diabetes mellitus: four-year results of the Look AHEAD trial. Arch Intern Med 2010, 170:1566-1575.
37. American Diabetes Association Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 2013, 36:S67-S74.
38. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998, 352:837-853. UK Prospective Diabetes Study (UKPDS) Group.
39. Mitri J., Hamdy O. Diabetes medications and body weight. Expert Opin Drug Saf 2009, 8:573-584.
40. Purnell J.Q., Hokanson J.E., Marcovina S.M., et al. Effect of excessive weight gain with intensive therapy of type 1 diabetes on lipid levels and blood pressure: results from the DCCT. Diabetes Control and Complications Trial. JAMA 1998, 280:140-146.
41. Lachin J.M., Christophi C.A., Edelstein S.L., et al. Factors associated with diabetes onset during metformin versus placebo therapy in the diabetes prevention program. Diabetes 2007, 56:1153-1159.
42. Amori R.E., Lau J., Pittas A.G. Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis. JAMA 2007, 298:194-206.
43. Deacon C.F. Dipeptidyl peptidase-4 inhibitors in the treatment of type 2 diabetes: a comparative review. Diabetes Obes Metab 2011, 13:7-18.
44. Jacob S., Rabbia M., Meier M.K., et al. Orlistat 120 mg improves glycaemic control in type 2 diabetic patients with or without concurrent weight loss. Diabetes Obes Metab 2009, 11:361-371.
45. Norris S.L., Zhang X., Avenell A., et al. Pharmacotherapy for weight loss in adults with type 2 diabetes mellitus. Cochrane Database Syst Rev 2005, (1):CD004096.
46. Torgerson J.S., Hauptman J., Boldrin M.N., et al. XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes care 2004, 27:155-161.
47. Lovshin J.A., Drucker D.J. Incretin-based therapies for type 2 diabetes mellitus. Nat Rev Endocrinol 2009, 5:262-269.
48. Drucker D.J., Nauck M.A. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 2006, 368:1696-1705.
49. Sheridan C. SGLT2 inhibitors race to enter type-2 diabetes market. Nat Biotech 2012, 30:899-900.
50. Clar C., Gill J.A., Court R., et al. Systematic review of SGLT2 receptor inhibitors in dual or triple therapy in type 2 diabetes. BMJ 2012, 2:e001007. http://dx.doi.org/10.1136/bmjopen-2012-001007.
51. Lau D.C.W. Is surgery an option in the treatment of type 2 diabetes?. Can J Diabetes 2011, 35:85-86.
52. Leonetti F., Capoccia D., Coccia F., et al. Obesity, type 2 diabetes mellitus, and other comorbidities: a prospective cohort study of laparoscopic sleeve gastrectomy vs. medical treatment. Arch Surg 2012, 147:694-700.
53. Buchwald H., Estok R., Fahrbach K., et al. Weight and type 2 diabetes after bariatric surgery: systematic review and meta-analysis. Am J Med 2009, 122:248-256.
54. Dixon J.B., O'Brien P.E., Playfair J., et al. Adjustable gastric banding and conventional therapy for type 2 diabetes: a randomized controlled trial. JAMA 2008, 299:316-323.
55. Schauer P.R., Kashyap S.R., Wolski K., et al. Bariatric surgery versus intensive medical therapy in obese patients with diabetes. N Engl J Med 2012, 366:1567-1576.
56. Mingrone G., Panunzi S., De Gaetano A., et al. Bariatric surgery versus conventional medical therapy for type 2 diabetes. N Engl J Med 2012, 366:1577-1585.
57. Arterburn D.E., Bogart A., Sherwood N.E., et al. A multisite study of long-term remission and relapse of type 2 diabetes mellitus following gastric bypass. Obes Surg 2013, 23:93-102.